BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.91
-0.16 (-1.98%)
At close: Sep 12, 2025, 4:00 PM EDT
7.90
-0.01 (-0.13%)
After-hours: Sep 12, 2025, 7:16 PM EDT
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $163.35M in the quarter ending June 30, 2025, with 49.41% growth. This brings the company's revenue in the last twelve months to $557.51M, up 45.85% year-over-year. In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth.
Revenue (ttm)
$557.51M
Revenue Growth
+45.85%
P/S Ratio
2.95
Revenue / Employee
$961,217
Employees
580
Market Cap
1.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BCRX News
- 9 days ago - BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - BioCryst to Present at Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewsWire
- 5 weeks ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December - GlobeNewsWire
- 7 weeks ago - BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewsWire